In This Article:
NEW YORK, NY / ACCESSWIRE / March 18, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Nutanix, Inc. (NASDAQ:NTNX)
Class Period: March 1, 2018 - May 30, 2019
Lead Plaintiff Deadline: March 22, 2021
Nutanix, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: Nutanix had materially overstated its customer base and sales productivity, and that such overstatements would eventually cause the Company's stock price to drop dramatically.
Learn about your recoverable losses in NTNX: http://www.kleinstocklaw.com/pslra-1/nutanix-inc-loss-submission-form?id=13846&from=1
CytoDyn Inc. (OTCQB:CYDY)
Class Period: March 27, 2020 - March 9, 2021
Lead Plaintiff Deadline: May 17, 2021
The complaint alleges that throughout the class period CytoDyn Inc. made materially false and/or misleading statements and/or failed to disclose that: CytoDyn securities were actively traded over the counter (OTC) in the United States. While the exact number of Class members is unknown to Plaintiff at this time and can be ascertained only through appropriate discovery, Plaintiff believes that there are hundreds or thousands of members in the proposed Class. Record owners and other members of the Class may be identified from records maintained by CytoDyn or its transfer agent and/or OTC Markets and may be notified of the pendency of this action by mail, using the form of notice similar to that customarily used in securities class actions.
Learn about your recoverable losses in CYDY: http://www.kleinstocklaw.com/pslra-1/cytodyn-inc-loss-submission-form?id=13846&from=1
Neptune Wellness Solutions Inc. (NASDAQ:NEPT)
Class Period: July 24, 2019 - February 16, 2021
Lead Plaintiff Deadline: May 17, 2021
Neptune Wellness Solutions Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the cost of Neptune's integration of the assets and operations acquired in the SugarLeaf Acquisition would be larger than the Company had acknowledged, placing significant strain on the Company's capital reserves; (ii) accordingly, it was reasonably foreseeable that the company would need to conduct additional stock offerings to raise more capital; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.